Kim Reed

发表

Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials

R. Vitti, D. Dhoot, Alyson J. Berliner, 2022, Eye.

Retinal Fluid Volatility Associated with Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.

Justis P. Ehlers, S. Srivastava, R. Vitti, 2020, American journal of ophthalmology.

Proliferative Diabetic Retinopathy Events in Patients With Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials

I. Suñer, D. Do, C. Shah, 2022, Journal of vitreoretinal diseases.

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy

C. Wykoff, G. Yancopoulos, D. Weinreich, 2021, JAMA ophthalmology.

Consistency of Treatment Effect with Aflibercept by Baseline Factors in PANORAMA

D. Do, Alyson J. Berliner, H. Moini, 2023, Ophthalmology Retina.

INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES

Sumit Sharma, D. Dhoot, Alyson J. Berliner, 2020, Retina.

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.

B. Joondeph, J. Pearlman, C. Wykoff, 2023, JAMA ophthalmology.

Association of Early Anatomic Response with Visual Function in Neovascular AMD.

Rishi P. Singh, R. Vitti, D. Eichenbaum, 2021, Ophthalmology.

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

S. Sivaprasad, C. Wykoff, G. Yancopoulos, 2024, The Lancet.